A genome-wide association study of tramadol metabolism from post-mortem samples

Frank R. Wendt, Anna Liina Rahikainen, Jonathan L. King, Antti Sajantila, Bruce Budowle

Research output: Contribution to journalArticle

Abstract

Phase I tramadol metabolism requires cytochrome p450 family 2, subfamily D, polypeptide 6 (CYP2D6) to form O-desmethyltramadol (M1). CYP2D6 genetic variants may infer metabolizer phenotype; however, drug ADME (absorption, distribution, metabolism, and excretion) and response depend on protein pathway(s), not CYP2D6 alone. There is a paucity of data regarding the contribution of trans-acting proteins to idiosyncratic phenotypes following drug exposure. A genome-wide association study identified five markers (rs79983226/kgp11274252, rs9384825, rs62435418/kgp10370907, rs72732317/kgp3743668, and rs184199168/exm1592932) associated with the conversion of tramadol to M1 (M1:T). These SNPs reside within five genes previously implicated with adverse reactions. Analysis of accompanying toxicological meta-data revealed a significant positive linear relationship between M1:T and degree of sample polypharmacy. Taken together, these data identify candidate loci for potential clinical inferences of phenotype following exposure to tramadol and highlight sample polypharmacy as a possible diagnostic covariate in post-mortem genetic studies.

Original languageEnglish
Pages (from-to)94-103
Number of pages10
JournalPharmacogenomics Journal
Volume20
Issue number1
DOIs
StatePublished - 1 Feb 2020

Fingerprint Dive into the research topics of 'A genome-wide association study of tramadol metabolism from post-mortem samples'. Together they form a unique fingerprint.

Cite this